ストックスクリーナーアプリを入手
24.23
2.67%
0.63
Zymeworks Inc. (ZYME) 最新ニュース
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Zymeworks Announces Participation in Upcoming Investor Conferences - Sahm
Aug Weekly: Does Zymeworks Inc stock have upside surprise potentialGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences - TipRanks
Zymeworks executives head to two April healthcare investor events - Stock Titan
Published on: 2026-03-23 15:16:44 - baoquankhu1.vn
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Inc stock faces biotech volatility amid pipeline updates and market shifts - AD HOC NEWS
Will Zymeworks Inc benefit from rising consumer demand2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Experimental breast cancer drug shrinks tumors in 6 weeks at AACR 2026 - Stock Titan
Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology? - Sahm
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - Koreabizwire
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com Australia
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
A Look At Zymeworks (ZYME) Valuation After New AACR 2026 Antibody Drug Conjugate Pipeline Data - Sahm
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Prosight Management LP Cuts Stake in Zymeworks Inc. $ZYME - MarketBeat
Value Recap: Does Zymeworks Inc have strong EBITDA marginsTrade Analysis Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Zymeworks (NASDAQ:ZYME) Trading Up 9.7%What's Next? - MarketBeat
Assessing Zymeworks (ZYME) Valuation After Q4 Updates And Improved Clinical And Funding Outlook - Sahm
Zymeworks (ZYME) Price Target Raised to $48 by Evercore ISI Grou - GuruFocus
Will Zymeworks' (ZYME) Wider Losses and ESOP Shelf Offering Recast Its Long-Term Equity Story? - Sahm
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00 - MarketBeat
Zymeworks (ZYME) Rating Maintained, Price Target Raised to $46 b - GuruFocus
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value By Investing.com - Investing.com Canada
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com Nigeria
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Australia
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience By GuruFocus - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com Canada
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com South Africa
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
1.82%
大文字化:
|
ボリューム (24 時間):